Global Paliperidone Market Size, Status and Forecast 2021-2027

Paliperidone, sold under the trade name Invega among others, is a dopamine antagonist and 5-HT2A antagonist of the atypical antipsychotic class of medications. It is marketed by Janssen Pharmaceutica. Invega is an extended release formulation of paliperidone that uses the OROS extended release system to allow for once-daily dosing. Paliperidone is mainly used to treat schizophrenia and schizoaffective disorder. It is also used to treat mania and at lower doses as maintenance for bipolar disorder.

Market Analysis and Insights: Global Paliperidone Market
The global Paliperidone market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Paliperidone market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Paliperidone market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Paliperidone market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Paliperidone market.

Global Paliperidone Scope and Market Size
Paliperidone market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Paliperidone market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
1.5 mg Tablet
3 mg Tablet
6 mg Tablet
9 mg Tablet

Segment by Application
Adults
Adolescents

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Janssen Pharmaceutica
Mylan
Teva